5 results
To evaluate the safety, tolerability and efficacy of 3 doses of vernakalant (oral) (150 mg, 300 mg and 500 mg b.i.d.) administered for up to 90 days in subjects with sustained symptomatic atrial fibrillation (AF duration > 72 hours and &…
The primary objective of this pilot study is to determine the accuracy of measurement of the new Point of Care Test (POCT) glucose meter ACI3 from Roche Diagnostics on venous, arterial and capillary whole blood samples from adult hospital patients.…
Part A - CX-2009 Monotherapy: Every 21-Day Dosing RegimenThe primary objective of Part A is to determine the safety profile of CX-2009, the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the dose-limiting toxicities(DLTs) of CX-…
Primary objectiveThe primary objective is to evaluate whether a standard pre- and postdilatation of the modern DES results in a more optimal stent implantation compared to DS as evaluated by OCT in patients with stable coronary artery disease.…
The aim of this study is to determine the measurement accuracy of Roche Diagnostics' new Point of Care Test (POCT) glucose meter Cobas Pulse (formerly ACI3) on venous, arterial, and capillary whole blood samples from adult hospital patients…